EdiGene, Immunochina to develop CAR-T therapy

By The Science Advisory Board staff writers

EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.

Both companies have experience in late-stage hematological malignancies. Though strides have been made in the use of autologous T-cell therapies, they believe allogeneic T cells could also play an important role in future treatments, according to the companies.

No other details about the partnership were provided.

Copyright © 2020 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?